Statera Biopharma, Inc.

0.00 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 29.41% of the previous 18 July’s closed higher than June.

About Statera Biopharma, Inc.

Statera BioPharma, Inc. develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (Stat-401), and COVID-19 (stat-205) as well as expanding into fibromyalgia and multiple sclerosis.